Primary membranous nephropathy
Conditions
Brief summary
Disappearance rate (half-life) of anti-PLA2R antibodies.
Detailed description
Immunological remission defined as IFT negative., Efficacy on clinical disease activity, defined as either CR or PR at 12 months., Adverse events., Quality of life during obinutuzumab treatment.
Interventions
DRUGGazyvaro 1
DRUG000 mg concentrate for solution for infusion.
Sponsors
Radboud universitair medisch centrum Stichting
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disappearance rate (half-life) of anti-PLA2R antibodies. | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunological remission defined as IFT negative., Efficacy on clinical disease activity, defined as either CR or PR at 12 months., Adverse events., Quality of life during obinutuzumab treatment. | — |
Countries
Netherlands
Outcome results
None listed